News & Trends - Biotechnology

Australian biotech develops printable point-of-care COVID-19 diagnostic test

Health Industry Hub | June 1, 2020 |
[Total: 1    Average: 4/5]

Biotech News: Australian biotechnology enterprise The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time.

Life Science Biosensor Diagnostics (LSBD), a portfolio company of The iQ Group Global, entered into a development collaboration agreement with Harvard University this week to develop the test from the Australian-invented Biosensor Platform; a printable organic thin-film transistor ‘strip’ being developed by LSBD to put the power of accurate and timely diagnosis in the hands of patients and their primary health practitioners at point of care.

The high-profile collaboration involves a pilot study to integrate the Biosensor Platform with a special coating developed at the Wyss Institute that can detect IgM and/or IgG antibodies, which indicate a person’s current or previous exposure to the SARS-CoV-2 virus and, thus, a potential infection with COVID-19.

Register & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

The future of point of care diagnostics, the Biosensor Platform is being developed by LSBD to test for more than 130 indications, including tumour markers, allergens, hormones and communicable diseases. The flagship diagnostic device being developed from the Biosensor Platform is the Saliva Glucose Biosensor, the first non-invasive replacement for finger-prick blood glucose testing for diabetes management.

Based on the data generated in this pilot study, further development in partnership Harvard University could result in a chewing-gum-sized diagnostic ‘strip’ that can be used for COVID-19 testing at point of care, with the ability to be printed at scale at a low cost, and produce real-time results.

“At The iQ Group Global, our mission is to create the medicines of tomorrow. Never before has our mission been more relevant, nor more urgent,” Dr George Syrmalis, Group CEO and Chairman of The iQ Group Global said.

In alignment with the Government’s mental health initiative the #SelfcareInHealthcare campaign has been launched to support Pharma, Biotech and MedTech industry professionals. The initiative is supported by Medicines Australia, AusBiotech, MTAA and ARCS Australia. Learn more.

“We are thrilled to enter this landmark collaboration for Australian biotechnology with the world-renowned Wyss Institute at Harvard University. Dependent on the outcomes of this research, we may be in a position to provide the global healthcare system with a point-of-care test capable of detecting SARS-CoV-2 antibodies, with the ability to provide results in minutes. If the pilot study data is positive, this test has the potential to be used as a point-of-care screening and diagnostic tool, and pre-vaccination screening tests for when a COVID-19 vaccine is made available,” Dr Syrmalis said.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]

More


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]

More


Medical

Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]

More